Cefaly Technology, the creators of the first FDA-approved transcutaneous electrical nerve stimulation device, specifically authorized for use prior to the...
A new clinical trial reveals that Cefaly, from STX-Med, the first FDA-approved external trigeminal nerve stimulation device for the prevention...
A new study finds that Cefaly, the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for use prior to...
Cephalalgia, the official peer-reviewed medical journal of the International Headache Society, has just published positive results of the American multicentric...
A study to determine whether transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly device, from STX-Med, for episodic Migraine prevention,...
There are a significant number of patients with epilepsy who are drug-resistant and for whom resective procedures are not an option. For these patients, neuromodulation may be an option, including closed-loop stimulation...
NeuroPace, Inc. has announced that the FDA has on 14 November 2013, granted premarket approval for the NeuroPace RNS System,...
AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.
DyAnsys Inc. announced that the FDA has cleared its auricular neurostimulation device, Drug Relief, to be used as an aid...
This guide has therefore been prepared with the important objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.